Moteur de recherche d’entreprises européennes
Financement de l’UE (3 342 323 €) : Stabilisation ciblée des interactions protéine-protéine par de petites molécules Hor11/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Stabilisation ciblée des interactions protéine-protéine par de petites molécules
The goal of the TASPPI European Training Network (ETN) is the establishment of a highly interdisciplinary research and educational training platform for early stage scientists in the Chemical Life Sciences to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed up in a consortium comprising 5 partners from industry (AstraZeneca, GlaxoSmithKline, UCB, Lead Disocvery Center, Taros Chemicals) and 6 partners from academia (Universities of Dundee, Eindhoven, Leeds, Lille, Prague, and Siena). The scientific objective of the multi-sectorial Training Network is the development and implementation of a multidisciplinary technology platform bringing together structural molecular biology, chemical biology, cell biology, synthetic chemistry, and medicinal chemistry for the identification of Small-molecule Stabilizers of Protein-Protein Interactions (PPIs) as a novel class of therapeutic agents and basic research tool compounds. With this new technological approach we aim to address a number of unmet medical needs in the areas Cancer, Neurodegenerative Diseases (Alzheimer’s, Parkinson’s), Pulmonary Diseases, Inflammation and Metabolic Diseases (Diabetes).
| Glaxosmithkline Research & Development Ltd. | ? |
| Astrazeneca AB | 527 319 € |
| Celltech R&D Ltd. | 250 514 € |
| Centre National de la Recherche Scientifique CNRS | 262 876 € |
| LEAD DISCOVERY CENTER GmbH | 249 216 € |
| TAROS CHEMICALS GmbH & Co. KG | 249 216 € |
| TECHNISCHE UNIVERSITEIT EINDHOVEN | 766 123 € |
| UCB Biopharma | 0,00 € |
| Universita Degli Studi Di Siena | 258 061 € |
| University of Dundee | 273 288 € |
| University of Leeds | 273 288 € |
| Univerzita Karlova | 232 422 € |
https://cordis.europa.eu/project/id/675179
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Glaxosmithkline Research & Development Ltd., Londres, Royaume Uni.
